Humanigen Announces ZUMA-19 Abstract Accepted for Presentation at American Society of Hematology 2020 Annual Meeting
November 04 2020 - 4:05PM
Business Wire
Humanigen, Inc., (Nasdaq:HGEN) (“Humanigen”), a clinical
stage biopharmaceutical company focused on preventing and treating
an immune hyper-response called ‘cytokine storm’ by neutralizing
granulocyte-macrophage colony-stimulating factor (GM-CSF) with its
lead therapeutic candidate lenzilumab™, the company’s proprietary
Humaneered® anti-human-GM-CSF immunotherapy, today announced the
acceptance of an abstract describing the ongoing ZUMA-19 study for
presentation at the 62nd American Society of Hematology (ASH)
Annual Meeting & Exposition, to be held virtually from December
5-8, 2020.
“The rationale for GM-CSF neutralization with CAR-T cell therapy
is appealing and well-understood and we look forward to discussing
this ongoing trial at ASH in collaboration with our research
partners,” said Cameron Durrant, MD, MBA, chief executive officer
of Humanigen.
ZUMA-19 is a joint Humanigen/Kite, a Gilead Company, clinical
study that is being conducted as part of a clinical collaboration
in the US. The ongoing ZUMA-19
Phase 1b/2 multicenter study is evaluating lenzilumab in
adults with relapsed/refractory large B-cell lymphoma (R/R LBCL)
who are receiving CAR-T cell therapy with axicabtagene
ciloleucel.
The abstract, titled “ZUMA-19: A Phase 1/2 Multicenter Study of
Lenzilumab Use with Axicabtagene Ciloleucel (Axi Cel) in Patients
(Pts) With Relapsed or Refractory Large B Cell Lymphoma (R/R
LBCL),” will be presented as a Trials-in-Progress poster (Abstract
#2103) on Sunday, December 6 at 10:00 a.m. ET.
About Humanigen, Inc.
Humanigen, Inc. is developing its portfolio of clinical and
pre-clinical therapies for the treatment of cancers and infectious
diseases via its novel, cutting-edge GM-CSF neutralization and
gene-knockout platforms. We believe that our GM-CSF neutralization
and gene-editing platform technologies have the potential to reduce
the inflammatory cascade associated with coronavirus infection. The
company’s immediate focus is to prevent or minimize the cytokine
release syndrome that precedes severe lung dysfunction and ARDS in
serious cases of SARS-CoV-2 infection. The company is also focused
on creating next-generation combinatory gene-edited CAR-T therapies
using strategies to improve efficacy while employing GM-CSF gene
knockout technologies to control toxicity. In addition, the company
is developing its own portfolio of proprietary first-in-class
EphA3-CAR-T for various solid cancers and EMR1-CAR-T for various
eosinophilic disorders. The company is also exploring the
effectiveness of its GM-CSF neutralization technologies (either
through the use of lenzilumab™ as a neutralizing antibody or
through GM-CSF gene knockout) in combination with other CAR-T,
bispecific or natural killer (NK) T cell engaging immunotherapy
treatments to break the efficacy/toxicity linkage, including to
prevent and/or treat graft-versus-host disease (GvHD) in patients
undergoing allogeneic hematopoietic stem cell transplantation
(HSCT). Additionally, Humanigen and Kite, a Gilead Company, are
evaluating lenzilumab in combination with axicabtagene ciloleucel
in patients with relapsed or refractory large B-cell lymphoma in a
clinical collaboration. For more information, visit
www.humanigen.com.
Forward-Looking
Statements
This release contains forward-looking statements.
Forward-looking statements reflect management's current knowledge,
assumptions, judgment and expectations regarding future performance
or events. Although management believes that the expectations
reflected in such statements are reasonable, they give no assurance
that such expectations will prove to be correct and you should be
aware that actual events or results may differ materially from
those contained in the forward-looking statements. Words such as
"will," "expect," "intend," "plan," "potential," "possible,"
"goals," "accelerate," "continue," and similar expressions identify
forward-looking statements, including, without limitation,
statements regarding the potential for lenzilumab to be used to
prevent or treat COVID-19, GvHD and, as sequenced therapy with
Kite’s axicabtagene ciloleucel, in CAR-T therapies. Forward-looking
statements are subject to a number of risks and uncertainties
including, but not limited to, the risks inherent in our lack of
profitability; our dependence on partners to further the
development of our product candidates; the costs and the
uncertainties inherent in the development, attainment of requisite
regulatory approvals and launch of any new pharmaceutical product;
the outcome of pending or future litigation; and the various risks
and uncertainties described in the "Risk Factors" sections and
elsewhere in the Company's periodic and other filings with the
Securities and Exchange Commission.
All forward-looking statements are expressly qualified in their
entirety by this cautionary notice. You should not place undue
reliance on any forward-looking statements, which speak only as of
the date of this release. We undertake no obligation to revise or
update any forward-looking statements made in this press release to
reflect events or circumstances after the date hereof or to reflect
new information or the occurrence of unanticipated events, except
as required by law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20201104005710/en/
Media Cammy Duong Westwicke, an ICR company
Cammy.duong@westwicke.com 203-682-8380
Investors Alan Lada Solebury Trout
ALada@SoleburyTrout.com 617-221-8006
Humanigen (NASDAQ:HGEN)
Historical Stock Chart
From Aug 2024 to Sep 2024
Humanigen (NASDAQ:HGEN)
Historical Stock Chart
From Sep 2023 to Sep 2024